Unique ID issued by UMIN | UMIN000052187 |
---|---|
Receipt number | R000059560 |
Scientific Title | A verification study of the improving effect of consumption of the test food on sleep quality: a randomized, placebo-controlled, double-blind, parallel-group comparison study |
Date of disclosure of the study information | 2023/09/12 |
Last modified on | 2024/04/17 10:09:27 |
A verification study of the improving effect of consumption of the test food on sleep quality
A verification study of the improving effect of consumption of the test food on sleep quality
A verification study of the improving effect of consumption of the test food on sleep quality: a randomized, placebo-controlled, double-blind, parallel-group comparison study
A verification study of the improving effect of consumption of the test food on sleep quality
Japan |
Healthy Japanese subjects
Not applicable | Adult |
Others
NO
To verify the improving effects of consumption of the test food on sleep quality
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
1. "Initiation and maintenance of sleep" in the OSA sleep inventory MA version (OSA-MA) at 12 weeks after consumption (12w)
1. "Sleepiness on rising", "frequent dreaming", "refreshing", "sleep length", and each item in the OSA-MA at 12w
2. The total score, "Sleep quality"(C1), "Sleep latency"(C2), "Sleep duration"(C3), "Habitual sleep efficiency"(C4), "Sleep disturbance"(C5), "Use of sleeping medication"(C6), "Daytime dysfunction"(C7), and each item in the Japanese version of the Pittsburgh Sleep Quality Index at 12w
3. Each item in the St. Mary's Hospital sleep questionnaire at 12w
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
Institution is not considered as adjustment factor.
YES
2
Treatment
Food |
Duration: 12 weeks
Test food: Tablet containing garlic extract powder
Administration: Take two tablets per day with water within 30 minutes after breakfast.
*If you forget to take the test food, take it as soon as you remember. Daily dose should be taken within the day and not carried over to the next day.
Duration: 12 weeks
Test food: Placebo tablet
Administration: Take two tablets per day with water within 30 minutes after breakfast.
*If you forget to take the test food, take it as soon as you remember. Daily dose should be taken within the day and not carried over to the next day.
18 | years-old | <= |
Not applicable |
Male and Female
1. Japanese
2. Men or women
3. Adults
4. Healthy subjects
5. Subjects who are judged as eligible to participate in the study by the physician according to the results of the Beck Depression Inventory (BDITM-II) at screening (before consumption)
1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction
2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Subjects currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Subjects who are currently undergoing treatment of insomnia or sleep disorder
5. Subjects who use or take "Foods for Specified Health Uses," or "Foods with Functional Claims" in daily
6. Subjects who are currently taking medications (including herbal medicines) and supplements
7. Subjects who are allergic to medicines and/or the test food related products
8. Subjects who live with their infants less than one year old
9. Subjects who sleep with their children (one to six years old)
10. Subjects who live with requiring long-term care persons
11. Subjects who sleep with more than one person
12. Subjects whose sleeping time or habit is irregular due to work such as a late-night shift
13. Subjects whose dinner time is irregular
14. Subjects who are pregnant, lactating, or planning to become pregnant during this trial
15. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
16. Subjects who are judged as ineligible to participate in this study by the physician
40
1st name | Tsuyoshi |
Middle name | |
Last name | Takara |
Medical Corporation Seishinkai, Takara Clinic
Director
141-0022
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
t-takara@takara-clinic.com
1st name | Naoko |
Middle name | |
Last name | Suzuki |
ORTHOMEDICO Inc.
R&D Department
112-0002
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
03-3818-0610
nao@orthomedico.jp
ORTHOMEDICO Inc.
Bizen Chemical Co., Ltd.
Profit organization
Medical Corporation Seishinkai, Takara Clinic
Nerima Medical Association, Minami-machi Clinic
the ethical committee of the Takara Clinic, Medical Corporation Seishinkai
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
IRB@takara-clinic.com
NO
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
2023 | Year | 09 | Month | 12 | Day |
Unpublished
44
Completed
2023 | Year | 08 | Month | 23 | Day |
2023 | Year | 08 | Month | 23 | Day |
2023 | Year | 09 | Month | 12 | Day |
2024 | Year | 02 | Month | 25 | Day |
2023 | Year | 09 | Month | 12 | Day |
2024 | Year | 04 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059560